



Wobenzymes for Joint Disease

Wobenzym N systemic oral combination enzymes may be extremely beneficial in cases of difficult-to-treat joint and inflammatory disease. Of particular note is their ability to help children's juvenile chronic arthritis.

By Michael Loes, M.D, M.D.(H.)

From The Doctors' Prescription For Healthy Living — Volume 2, Number 5

Both rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) often present as progressive disabling diseases. RA and SLE frequently cause internal organ damage secondary to chronic inflammatory responses. These inflammatory responses can be modulated, and arrested before irreversible damage ravages an individual. These types of patients are some of the most difficult patients a pain specialist sees. A balanced approach must be considered - one that uses the best conventional medicine, as well as nutritional, and alternative strategies available to preserve life and function.

The drugs that we use such as non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, gold salts and methotrexate are of some benefit but are extremely toxic and can result in damage to the bones and joint matrix. And when it comes to young children and inflammatory diseases, we still have only these extremely toxic drugs. It is tough to see young children on corticosteroids, but doctors try to control the complications the best that we can.

Now, thanks to a mountain of evidence, we know that a specific combination of systemic oral enzymes called Wobenzym® N, available at health food stores, may be one of the best medicines for both adults and children with difficult-to-treat inflammatory/joint conditions.

In both rheumatoid arthritis and SLE, the immune system is out of control and turns on the body. Although medical science is unsure of the exact cause of either rheumatoid arthritis or SLE, we do know that for some reason the body's immune system begins to form antibodies that cause a chronic inflammation of the joints.

Enzymes Accelerate Elimination of Circulating Immune Complexes

Both rheumatoid arthritis and SLE are immune and inflammatory diseases, but few conventional treatments address their underlying systemic condition. Most treatments reduce the inflammation and pain but do nothing to start the healing process. In this sense, enzymes may be superior. Their influence on the immune system is profound and they stimulate healthy production of cytokines that quench inflammation and rev up immunity to produce a cleansing effect, helping to cleave or break up circulating immune complexes (CICs) at the center of the body's RA or SLE immune/inflammation firestorm.

Enzymes and Difficult-to-Treat Rheumatoid Arthritis

In rheumatoid arthritis, the thin membrane surrounding the joints (synovium) becomes swollen and extremely inflamed. As these attacks continue to occur, the bones and joint tissues are weakened and eventually destroyed, destroying the integrity of the joint, including the cartilage which provides a cushioning effect.

By knocking down inflammation, enzymes allow healing to occur. A sampling of the studies on Wobenzym N:

- Excellent early results using the patented enzyme formula Wobenzym N were noted by researchers writing in 1985 in *Zeitschr. f. Rheumatologie*. In this study, patients took eight Wobenzym N tablets four times daily. Sixty-two percent of patients improved.
- A 1988 report in *Naturund Ganzheitsmedizin* showed that the same formula can prevent further flare-ups and helps to lower levels of inflammatory-related circulating immune complexes in rheumatoid arthritis patients.
- Another study also published in *Naturund Ganzheitsmedizin* in 1988 noted that Wobenzym N has demonstrated produced similar benefits to gold therapy but without toxic side effects.
- Most recently, researchers from the Ukrainian Rheumatology Centre, in Kiev, tested Wobenzym on 78 patients with severe, crippling RA and who were using other prime treatment drugs.

All of the RA patients showed a decrease in CIC concentrations, averaging between 28 and 42 percent, and decreases in rheumatoid factors. **Twenty percent** of patients reduced their NSAID doses by 50 to 75 percent. One patient stopped taking methotrexate and experienced a clinical remission of the disease. Morning stiffness scores improved. More than half the patients rated their treatment with Wobenzym as good, compared to only about a third of the patients using only medical drugs.

""The study results therefore confirm that Wobenzym is a new and quite effective antirheumatic agent, which also presents the properties of a second-line agent,"" said the Russian researchers at the Second Russian Symposium on Oral Enzyme Therapy in St. Petersburg, Russia, 1996.

At this same conference, researchers presented findings on Wobenzym and juvenile arthritis. In the study, among 10 children from the Paediatric Clinic of the Institute of Rheumatology of the Russian Academy of Medical Science, 10 children with JCA were given five tablets three times a day. They could also receive treatment with one NSAID in addition to Wobenzym. In the children, the number of actively inflamed joints was reduced from

441015, especially in the second month. One patient with psoriatic arthritis experienced a significant reduction in dermal signs of the disease. The drug proved effective generally after four to five months of treatment.

Enzymes Benefit Persons with SLE

Systemic lupus erythematosus (SLE lupus) most often strikes young women (between the ages of 20 to 40).

The condition is characterized by severe fatigue and butterfly rash across the face; debilitating pain and swelling often occur in the hands, wrists, elbows, knees, ankles, or feet. There may also be morning stiffness in the joints. Other signs and symptoms of lupus include a worsening of the butterfly rash across the face following sun exposure; a pale or blue tinge to the fingers when exposed to cold; and possibly hair loss.

Lupus is a serious condition because it may also cause diseases of the internal organs, including the heart, brain, lungs, and kidneys, as well as bleeding, anemia, and chronic infections. With proper treatment, however, lupus can be controlled, and sufferers can expect normal life expectancy.

While lupus is usually not a primary cartilage destroying disease, people with lupus may be put on high dose steroids for long periods of time and their joints wear out sooner.

Enzymes also help to dissolve circulating immune complexes and antibodies that cause severe inflammation of SLE. According to D.A. Lopez, M.D., associate clinical professor of medicine at the University of California at San Diego Medical School and co-author of *Enzymes: The Fountain of Life*, animals suffering from this inflammatory condition, when given combination enzymes, have shown significant improvement.

In one study of SLE patients presented at the 1996 Russian Symposium, 18 patients were selected with an age range of only 18 to 46; yet, already their lives were crippled with kidney disease, severe inflammation, and some needing canes.

In SLE patients given Wobenzym N, inflammatory activity of the disease regressed quickly during treatment than in patients not treated with the drug. This was shown by a decrease in tendency to hemorrhage. There were decreases in CICs.

Five patients taking Wobenzym were able to reduce their dose of Voltaren or prednisolone. This is important because these drugs are not without complications.

Enzymes may be particularly important for SLE sufferers for another reason: they've been strongly shown to help prevent kidney disease and failure, both of which are commonly associated with SLE, according to August Heidland, M.D., and co-investigators reporting in a 1997 issue of *Kidney International*.

Wobenzym N; Important Treatment for RA and SLE

I now consider Wobenzym N to be an exciting strategy with a known track record to include in the treatment of rheumatoid arthritis and other immune complex diseases. It just makes sense. The data are there. The use of Wobenzym N is a biological strategy that should preserve tissue and clear up inflammation faster and more completely. It has potential to be

an effective and safer alternative treatment than employing large dose, long-term NSAIDs and steroids. It hits the inflammatory cascade to bring it under control.

The historical track record of Wobenzym N is extensive in regards to safety and efficacy. Its use should increase as the German studies are translated and brought into the mainstream of information available to heal arthritis safely and quickly."

References

- Heidland, A., et al. "Renal fibrosis: role of impaired proteolysis and potential therapeutic strategies." *Kidney International*, 1997; 52 (suppl. 62). Paper in press at time of publication; page numbers not available.
- Mazurov, V.I., et al. "Systemic enzyme therapy in combination therapy for rheumatic disease." *Oral Enzyme Therapy. Compendium of Results from Clinical Studies with Oral Enzyme Therapy. Second Russian Symposium, St. Petersburg, Russia, 1996.*
- Miehike, K. "Enzymtherapie bei rheumatoider arthritis." *Nature- und Ganzheitsmedizin*, 1988; 1: 108.
- Shaikov, A.V., et al. "Wobenzym in combination therapy for juvenile chronic arthritis." *Oral Enzyme Therapy. Compendium of Results from Clinical Studies with Oral Enzyme Therapy. Second Russian Symposium, St. Petersburg, Russia, 1996, pp. 28-32.*
- Steffen, C., et al. "Enzymtherapie im vergleich mit immunkomplexbestimmungen bei chronischer polyarthritis.." *Zeitschr. f. Rheumatologie*, 1985; 44: 51.
- Streichhan, P., et al. "Resorption partikularer und makromolekularer Darminhaltsstoffe." *Nature-und Ganzheitsmedizin*, 1988; 1: 90.